search icon
      blog search icon

      BCRX Stock Price History and Quote Analysis: Insights for Investors

      BioCryst Pharmaceuticals, Inc.

      (NASDAQ:BCRX)

      $5.69

      0.02 (0.35%)

      At Close: 4:00 PM

      BCRX Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      BCRX Stock Price Today

      BioCryst Pharmaceuticals, Inc. (BCRX) stock rallied over 0.35% intraday to trade at $5.69 a share on NASDAQ. The stock opened with a loss of -3.53% at $5.47 and touched an intraday high of $5.53, rising 0.35% against the last close of $5.67. The BioCryst Pharmaceuticals, Inc. in stock market went to a low of $5.23 during the session.

      BCRX Stock Snapshot

      $5.67

      Prev. Close

      1.17 Billion

      Market Cap

      $5.23

      Day Low

      $5.47

      Open

      N/A

      Number of Shares

      $5.53

      Day High

      N/A

      P/E ratio

      -1.25

      EPS (TTM)

      1.94

      Cash Flow per Share

      N/A

      Free Float in %

      -2.16

      Book Value

      5120120.00

      Volume

      BCRX Stock Price History Chart

      DateOpenHighLowCloseVolume

      Contact Details

      4505 Emperor Boulevard
      Durham, NC 27703
      US

      Website:https://www.biocryst.com

      Contact #:919 859 1302

      Company Information

      EmployeesN/A

      Beta1.90

      Sales or Revenue$317.56 Million

      5Y Sales Change181.93%

      Fiscal Year EndsDec. 2022

      SectorHealthcare

      IndustryBiotechnology

      About Company

      BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

      Peers

      Frequently Asked Questions

      icon

      What is the current BioCryst Pharmaceuticals, Inc. (BCRX) stock price?

      BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) stock price is $5.69 in the last trading session. During the trading session, BCRX stock reached the peak price of $5.53 while $5.23 was the lowest point it dropped to. The percentage change in BCRX stock occurred in the recent session was 0.35% while the dollar amount for the price change in BCRX stock was $0.02.

      icon

      BCRX's industry and sector of operation?

      The NASDAQ listed BCRX is part of Biotechnology industry that operates in the broader Healthcare sector. BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers novel, oral, and small-molecule medicines.

      icon

      Who are the executives of BCRX?

      Ms. Alane P. Barnes
      Senior Vice President, Chief Legal Officer & Corporation Sec.
      Mr. Jon P. Stonehouse
      Chief Executive Officer, Pres & Executive Director
      Mr. Michael L. Jones
      Executive Director of Fin. & Principal Accounting Officer
      Mr. Anthony J. Doyle
      Senior Vice President & Chief Financial Officer

      icon

      How BCRX did perform over past 52-week?

      BCRX's closing price is 0.18% higher than its 52-week low of $5.23 where as its distance from 52-week high of $14.2 is -0.45%.

      icon

      How many employees does BCRX have?

      Number of BCRX employees currently stands at N/A. BCRX operates from 4505 Emperor Boulevard, Durham, NC 27703, US.

      icon

      Link for BCRX official website?

      Official Website of BCRX is: https://www.biocryst.com

      icon

      How do I contact BCRX?

      BCRX could be contacted at phone #919 859 1302 and can also be accessed through its website. BCRX operates from 4505 Emperor Boulevard, Durham, NC 27703, US.

      icon

      How many shares of BCRX are traded daily?

      BCRX stock volume for the day was 5120120.00 shares. The average number of BCRX shares traded daily for last 3 months was 3.35 Million.

      icon

      What is the market cap of BCRX currently?

      The market value of BCRX currently stands at $1.17 Billion with its latest stock price at $5.69 and N/A of its shares outstanding.